Moderna (MRNA) is set for three data readouts on its individualized neoantigen therapies, or INT, in the near term, serving as potential stock catalysts for the company, UBS Secur ...

Shares of Moderna ( MRNA) rose 177% in Wednesday trading, while Merck’s ( MRK) rose some 12%, after the pharma companies announced positive results from a late-stage trial of an experimental ...

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

Moderna's upside hinges on Intismeran’s ability to scale across multiple tumor types, not just melanoma. Learn why MRNA stock ...

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, ...

Simon Baker, Rothschild & Co Redburn global biopharma research co-head, joins 'Squawk on the Street' to discuss Moderna and Merck shares surging after an experimental personalized cancer vaccine from ...

Today, Aug. 19, 2026, Moderna's personalized cancer vaccine met its late-stage goal, with the company and Merck planning an FDA submission.